$ZDGE

Zedge (NYSE: ZDGE) posts Q2 2026 growth with record monetization and cash

Zedge (NYSE: ZDGE) reported strong second-quarter fiscal 2026 results, with revenue climbing 18% year-over-year to $8.3 million, driven by significant growth in advertising and subscriptions. Despite a GAAP net loss of $2.3 million due to an intangible asset impairment, the company saw improved non-GAAP net income of $0.8 million and Adjusted EBITDA of $1.1 million, alongside increased free cash flow and a healthy cash balance. Zedge also highlighted progress in its DataSeeds AI training data business and ongoing innovation with new alpha product launches.

Original reporting
Published Mar 13, 2026, 7:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Mar 13, 2026, 8:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$ZDGE
Neutral
medium confidence
Mentioned
$ZDGE
AlphAI data visualization · based on Stock Titan
Decision brief

The 30-second read

$ZDGENeutralMed
01

Why it matters

The earnings report indicates growth in revenue but also highlights profitability challenges, influencing investor sentiment and stock performance.

02

Market read

The company's growth signals and strategic initiatives are relevant for investors interested in digital content and AI sectors.

03

What to watch

Potential market overreaction to short-term results; upcoming product launches and AI initiatives could alter the company's trajectory.

Timing: Immediate, given recent earnings release

Background

Zedge is a digital content and monetization platform with recent focus on AI data services and product innovation.

Company-level read

Ticker impact

$ZDGENeutralMedium confidence
Context

The company's recent quarterly results and growth indicators suggest some positive momentum, but the overall impact on stock price remains uncertain due to mixed financials.

Expected impact

Potential modest upward movement in the short term, contingent on market perception of growth and profitability improvements.

Evidence & confidence

While revenue growth is positive, the net loss and impairment suggest caution. The company's strategic initiatives could lead to future gains, but current financials warrant a balanced outlook.

Market effects

Positive sentiment for the technology and digital services sector, especially companies involved in AI and digital monetization.

Limited regional impact, primarily affecting US-based tech stocks.

Moderate, as Zedge's growth signals could influence similar companies globally.

Counterpoint

The recent growth may be a temporary spike; the company's ongoing losses and impairments could signal underlying issues that may limit upside.

Key entities

  • Zedge Inc.

    A provider of digital content and monetization services.

  • DataSeeds AI

    AI training data business segment of Zedge.

Related articles

$ZDGEMed

Zedge Reports Third Quarter Fiscal 2026 Results

Zedge, Inc. (ZDGE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ea029448101ex99-1.htm EARNINGS RELEASE, DATED JUNE 11, 2026, REPORTING THE RESULTS OF OPERATIONS FOR ZEDGE, INC.'S FISCAL QUARTER ENDED APRIL 30, 2026 Exhibit 99.1 Zedge Reports Third Quarter Fiscal 2026 Results Subscription revenue increased 32%, and active subscriptio

$SNPSMedAI 8/10

Synopsys signs $1bn-plus silicon IP deal with Amazon

Synopsys signed a multi-year, $1bn+ deal with Amazon for silicon IP solutions, making Amazon its lead customer. The agreement includes a license-plus-royalty model and collaboration on AI-driven chip design. Synopsys will also use Amazon's cloud services. Separately, Synopsys partnered with OpenAI to develop GPT-Synopsys for semiconductor design workflows.

$SYREMed

JPMorgan initiates Spyre stock with Overweight on IBD pipeline

JPMorgan initiated Spyre Therapeutics (NASDAQ:SYRE) with an Overweight rating and a $110 price target, citing its IBD pipeline and combination therapy potential. The stock has gained 441% in the past year. Other analysts have mixed views, with some downgrading due to valuation concerns and others maintaining Buy ratings. Spyre reported Phase II results for its rheumatoid arthritis program, which showed efficacy but did not meet internal thresholds for monotherapy prioritization.

$ELVNMed

Enliven Therapeutics stock initiated at Overweight by JPMorgan

JPMorgan initiated coverage on Enliven Therapeutics (ELVN) with an Overweight rating and a $75 price target, implying 64% upside. The stock has surged 198% year-to-date. Analysts highlight ELVN-001's potential in treating chronic-phase CML, with U.S. peak sales estimated at $5 billion. Recent reports from William Blair, Barclays, and Guggenheim also show positive outlooks.